HIGHLIGHTS: Thomas Schinecker - CEO of Roche

Episode Summary

Executive Summary: Nicola Tangen interviews Roche CEO Thomas Schineker about Basel’s biopharma ecosystem, major advances in cancer treatment, Roche’s strong pipeline, and the company’s work on brain-shuttle technology for difficult-to-treat diseases like Alzheimer’s. Schineker also argues that Europe must cut bureaucracy and improve startup funding to remain competitive with the US and China, while defending pharma pricing as necessary to sustain long-term innovation.

Main Topics: Basel as a global biopharma hub: Schineker explains that Basel’s strength comes from its chemical-industry roots, central European location, and strong universities that attract global talent. Cancer innovation and treatment breakthroughs: He highlights genome sequencing and antibody-based therapies as key milestones that improved the ability to target cancer’s root causes and activate the immune system. Roche pipeline and medicine development cadence: The discussion covers Roche’s 20-product pipeline, the difficulty of drug development, and the company’s goal of sustaining a pace of about two new medicines per year. Brain-shuttle technology and Alzheimer’s research: Schineker describes a technology designed to help large molecules cross the blood-brain barrier, enabling better treatment of brain diseases and a promising Alzheimer’s candidate. Europe’s competitiveness in life sciences: He argues that Europe is losing ground to the US and China because of weaker venture-capital support, talent migration, and excessive bureaucracy around clinical trials. Drug pricing and the economics of innovation: Schineker defends high prices as a mechanism to recover the massive cost and risk of drug development and to fund future innovation that later becomes widely accessible. Leadership and purpose at Roche: He emphasizes company culture, long tenure, and the emotional reward of seeing clinical trials succeed and improve patients’ lives.

Key Arguments: Basel became a biopharma center because historical chemical-industry capabilities, geography, and education created a strong innovation ecosystem. Cancer outcomes improved dramatically because genome sequencing revealed biological drivers and antibodies enabled more precise and immune-based therapies. Roche’s innovation pace is strong: roughly two new medicines a year, despite long development timelines and high attrition. Brain-shuttle technology could unlock treatments for diseases in the brain by helping antibodies cross the blood-brain barrier. Europe must improve access to venture capital and reduce regulatory bureaucracy or it will continue losing clinical-trial and biotech activity to the US and China. Drug prices reflect the need to recoup the costs of 13-year development cycles and low success rates, and they finance medicines that later become essential globally. Working in pharma is purpose-driven because successful trials can change patients’ lives in visible, emotional ways.

Data Points: Roche ownership by Norwegian Sovereign Wealth Fund: 2.3% - Nicola Tangen notes the fund’s stake in Roche Value of Roche stake: more than $6 billion - Nicola Tangen describes the fund’s investment Roche founding year: 1896 - Introduced as part of Roche’s long history Genome sequencing cost (past): billions of dollars - Schineker contrasts early genome sequencing with today Genome sequencing time (past): more than 10 years - Historical sequencing timeline Genome sequencing cost (today): hundreds of Swiss francs or dollars - Current affordability of sequencing Genome sequencing time (today): within just days - Current turnaround time Average time to develop a medicine: around 13 years - Industry-wide drug development timeline Medicine success rate: about 1 out of 10 - Industry-wide probability of a candidate reaching launch Roche launch pace: about 2 new medicines every year - Average over the last 10 to 15 years Pipeline size: 20 new products - Schineker references Roche’s pipeline Already launched from pipeline: 9 launched - Referenced in the prior call mentioned by the interviewer Expected Alzheimer’s launch window: 2028-2029 - Target timeframe for a promising Alzheimer’s medicine using brain-shuttle technology Europe clinical-trial share change: halved over the last 10 years - Interviewer notes Europe’s decline versus China and the US Time to start a clinical trial in some European countries: about 1 year - Example used to illustrate regulatory delay Time to earn back R&D investment: around 10 years - Schineker discusses the pricing and innovation model WHO essential medicines from Roche history: 44 medicines - He cites the long-term societal benefit of past innovation

Pivotal Quotes: "I think it's all in the history of that region." — Thomas Schineker: Explaining why Basel became a major biopharma center "Now you can do that within just days, and it costs you hundreds of Swiss francs or dollars" — Thomas Schineker: Describing the drop in genome sequencing cost and time as a breakthrough for oncology "If it takes you a year from the time you apply for clinical trial to being able to start a clinical trial, that's a year of lost time" — Thomas Schineker: Arguing that European bureaucracy slows medical innovation and delays patient benefit

Implications: The conversation suggests future biopharma leadership will depend on fast science, better regulation, and sustained incentives for innovation. Europe risks further decline unless it improves funding and bureaucracy, while technologies like brain shuttles may expand treatment options for brain diseases.